Clinical Trial: Cancer, MSK, Genomic


Full Name

Genomic Profiling in Cancer Patients


The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison.


Inclusion Criteria

Part A:

  • Patients with cancer or other related disorders

Part B:

  • Patients successfully registered to Part A of (MSKCC IRB # 12-245)
  • Prior written approval for patient consent obtained from Director of the Center fo Molecular Oncology, or a Principal/Co-Principal Investigator of MSKCC IRB # 12-245.

Part C:

  • Patient must be receiving ongoing care at MSK or an Alliance/Affiliate site.
  • Patient must have successfully consented to Part A of this study.
Exclusion Criteria
  • Unwilling or unable to provide informed consent.
Doctor(s) Running This Study


  • Hematology/Medical Oncology

Area of focus i

  • Melanoma
  • Kidney cancer (renal cancer)
  • Sarcoma

Affiliated with

LVPG Cliniciani

Accepting New Patients